Please provide your email address to receive an email when new articles are posted on . The study treatment, PT027, is a potential first-in class inhaled, fixed-dose combination rescue medication ...

Findings from a trial comparing the real-world effectiveness of asthma inhalers could reshape how children with asthma are treated. In the first randomized controlled trial to investigate the use of a ...

August 22, 2008 — A budesonide/formoterol (Symbicort, AstraZeneca) pressurized metered-dose inhaler (pMDI) showed safety and better asthma control versus budesonide alone, according to the results of ...

(Logo: http://www.newscom.com/cgi-bin/prnh/20091027/PH99766LOGO) SYMBICORT is a combination asthma medication that contains both an inhaled corticosteroid (ICS ...

Two drugs are better than one when it comes to stopping asthma attacks in progress, a new clinical trial has found. The study, of more than 3,100 asthma patients, found that a two-drug "rescue" ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AIRSUPRA’s US Prescribing Information now includes clinically meaningful evidence from the BATURA study in patients with mild asthma. 1 The BATURA Phase IIIb trial, ...

If budesonide-formoterol were to become available over the counter (OTC) and used as-needed for mild asthma, it would save lives and cut healthcare costs, according to a computer modeling study ...

WILMINGTON, Del.--(BUSINESS WIRE)-- AstraZeneca (NYSE:AZN) today announced the publication of data demonstrating that SYMBICORT Inhalation Aerosol 320/9 µg twice daily had a safety profile similar to ...

Asthma-inhaler-resize_G_514410525 The SYGMA trials assessed the use of an as-needed combined corticosteroid/beta-agonist inhaler in patients with mild asthma. Level 2 ...

The Food and Drug Administration (FDA) has cleared the Propeller Health digital platform to connect with the Symbicort® Inhaler (budesonide, formoterol fumarate dihydrate; AstraZeneca), a ...

Young woman using asthma inhaler at home. The NDA submission is supported by data from the phase 3 MANDALA trial, which included 3132 patients with moderate to severe asthma. The Food and Drug ...

AstraZeneca today announced that the US District Court for the District of New Jersey ruled US Patent No. 7,524,834 ("the '834 patent"), protecting PULMICORT RESPULES in the US, is invalid.